Telomir Pharmaceuticals, Inc. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Telomir Pharmaceuticals announced peer-reviewed publication in Journal of Oncology Research and Therapy (Vol. 11, Issue 3) of preclinical data for lead candidate Telomir-Zn demonstrating suppression of tumor growth in triple-negative breast cancer (TNBC) and prostate cancer models through iron depletion and KDM inhibition. Iron-rescue experiments confirmed mechanism specificity; compound showed >50-fold selectivity for cancer over normal cells and reduced metastatic dissemination in HCC1806 xenografts. Company has active IND clearance and plans to advance Telomir-Zn into Phase 1/2 clinical trial in advanced/metastatic TNBC.
Why this rating
Peer-reviewed publication of robust preclinical mechanism-of-action data with iron-rescue proof de-risks lead program. For $18.1M-cap clinical-stage biotech, validation supporting Phase 1/2 initiation is meaningful catalyst, though preclinical stage limits impact certainty.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.